David Reardon

Understanding and Overcoming T Cell Immunosuppression in Glioblastoma

National Cancer Institute · P01

PI · $16.8M · Brigham and Women's Hospital

AHR-Mediated Immunosuppression in Glioblastoma

National Institute of Environmental Health Sciences · R01

PI · $867.7K · Brigham and Women's Hospital

SRC on Primary Tumors of the CNS

National Institute of Neurological Disorders and Stroke · P50

Project lead · $4.3M · Duke University

SPORE in Brain Cancer

National Cancer Institute · P50

Project lead · $1.1M · Duke University

CUE-102 in Recurrent Glioblastoma

Principal investigator · Recruiting · Phase 1

David Reardon, MD

ASP8374 + Cemiplimab in Recurrent Glioma

Principal investigator · Completed · Phase 1

Dana-Farber Cancer Institute

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Principal investigator · Completed · Phase 2

Dana-Farber Cancer Institute

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Principal investigator · Recruiting · Phase 2

David Reardon, MD